3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years

The article highlights three dividend-focused large caps as long-term income plays: AbbVie (yield ~2.9%) — a Dividend King with a 50+ year streak, a recent 5.5% dividend hike, sales up 8% to $44.5 billion through nine months and Skyrizi + Rinvoq generating $18.5 billion vs Humira’s $3.3 billion quarterly run-rate; Home Depot (yield ~2.7%) — 16 consecutive years of dividend increases, shares down ~13% YTD but management expects ~3% sales growth for the fiscal year ending January; and ExxonMobil (yield ~3.5%) — 43 years of annual dividend increases (avg ~5.8%), year-to-date earnings down $3.7 billion to $22.3 billion with EPS $5.16 versus annual dividends of $4.12, stock up ~8% YTD and trading around 16x forward earnings. The piece positions these names as diversified, cash-flow-generating holdings for income-oriented portfolios despite near-term consumer and commodity volatility.

Analysis

Market structure: Dividend-focused winners are large-cap cash-generative names (ABBV, XOM, HD) and income ETFs as investors rotate from growth into yield; small-cap growth and discretionary names are relative losers as capital reweights into defensive cash flow. AbbV's pivot from Humira to Skyrizi/Rinvoq (combined $18.5B YTD) strengthens pricing power in immunology, while XOM's cash-flow sensitivity to Brent ($55–80/bbl) keeps energy cyclicality central to equity returns. Bond yields and dividend stocks will trade inversely if the 10-year moves >50bp: higher rates compress HD more than XOM/ABBV due to duration differences.

Risk assessment: Tail risks include an AbbVie regulatory setback (FDA label loss or biosimilar shock) that could cut peak revenue >20% for a drug, an XOM oil-price collapse (<$50 Brent) reducing free cash flow >30%, or a US housing slump that knocks HD sales growth below 0% for two quarters. Near-term (days–weeks) drivers are earnings beats/misses and CPI; medium (3–12 months) is drug approvals/patents and winter oil demand; long-term (2–5 years) is secular healthcare pricing reform and energy transition capex. Hidden dependency: ABBV payout growth is concentrated in a few products—loss of one big win cascades to buybacks/dividend policy.

Trade implications: Direct plays — overweight ABBV (income + growth runway) and XOM (value + yield) while sizing HD as a tactical recovery trade only after confirmation of sales stability. Use covered calls on ABBV/XOM to harvest yield and sell 3–6 month OTM calls (5–7% OTM) to boost income; buy protective puts if Brent < $55 or AbbV downside >10%. Rotate 3–6% portfolio weight from growth tech into energy/healthcare dividend exposure over the next 4–8 weeks as rates stabilize.

Contrarian angles: Consensus understates AbbV's execution risk but overstates HD's secular demise — a 13% YTD HD selloff likely prices in a deeper housing collapse that historically hasn’t persisted more than 9–12 months. XOM's payout appears sustainable given trailing EPS vs annual dividend (~$5.16 vs $4.12 YTD), so upside is underappreciated if oil stays >$65 for next 6–12 months. Crowded dividend trade risks higher option IV and tighter spreads; consider pair hedges to avoid one-factor exposure.

Key Decisions for Investors

• Establish a 2–3% long position in ABBV within 0–4 weeks; simultaneously sell 3-month covered calls ~5% OTM to enhance yield, and buy a 6% OTM protective put if ABBV falls >10% from entry to limit downside.
• Add a 3–4% long position in XOM on pullback triggers of >5% or if Brent > $65 persists; hedge tail-risk by buying a 3–6 month $55 Brent put spread (sell $45 / buy $40) sized to cover 25–50% of position notional.
• Delay incremental HD exposure: open a 1% probe long only if shares drop an additional 8–12% or on a fiscal-quarter beat confirming >2% comparable sales growth; alternatively buy Jan 2026 LEAP calls (delta ~0.35) sized to 2% notional for convex upside.
• Implement a relative-value hedge: long ABBV (2%) vs short XBI or small-cap biotech ETF (1%) to neutralize sector regulatory risk; monitor FDA decisions and AbbV patent litigation closely over the next 30–90 days and adjust hedge if material rulings occur.